We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Catalyst Biosciences and Centocor R&D Form Collaboration to Discover and Develop Engineered Protease Therapeutics
News

Catalyst Biosciences and Centocor R&D Form Collaboration to Discover and Develop Engineered Protease Therapeutics

Catalyst Biosciences and Centocor R&D Form Collaboration to Discover and Develop Engineered Protease Therapeutics
News

Catalyst Biosciences and Centocor R&D Form Collaboration to Discover and Develop Engineered Protease Therapeutics

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Catalyst Biosciences and Centocor R&D Form Collaboration to Discover and Develop Engineered Protease Therapeutics"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Catalyst Biosciences, Inc. has announced that it has entered into an exclusive worldwide research and license agreement with Centocor Research & Development, Inc.

Through the collaboration, Centocor will support the discovery research and preclinical development by Catalyst of Alterase drug candidates against two targets, one of which is in inflammatory disease, with an option to expand the agreement to include a third target. Alterase therapeutics are next-generation, protease biologics engineered with the ability to catalytically cleave and inactivate disease-causing proteins.

Catalyst Biosciences will receive an upfront payment of $11 million, comprised of cash and an equity investment by Johnson & Johnson Development Corporation (JJDC), and will receive research funding for two years.

Centocor will be responsible for all development, manufacturing, and commercialization efforts associated with the Alterase products discovered through the collaboration in exchange for future milestones and royalties.

In conjunction with the equity investment and the signing of the agreement, Asish K. Xavier, Ph.D., of JJDC will join the Catalyst Biosciences Board of Directors.

"We are very pleased to collaborate with Centocor, a leading developer of biologic therapies, to employ our Alterase drug discovery engine against high-value targets," said Nassim Usman, Ph.D., Chief Executive Officer of Catalyst Biosciences. "We are also delighted to welcome JJDC to our premier group of investors."

Advertisement